Related references
Note: Only part of the references are listed.RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation
E. Jacque et al.
ONCOGENE (2013)
NF-κB, the first quarter-century: remarkable progress and outstanding questions
Matthew S. Hayden et al.
GENES & DEVELOPMENT (2012)
NF-κB: where did it come from and why?
Thomas D. Gilmore et al.
IMMUNOLOGICAL REVIEWS (2012)
Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors
Stephen T. Smale
IMMUNOLOGICAL REVIEWS (2012)
Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells
R. Schwarzer et al.
LEUKEMIA (2012)
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma
Luca Busino et al.
NATURE CELL BIOLOGY (2012)
Latest advances and current challenges in the treatment of multiple myeloma
Anuj Mahindra et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines
Stephan Hailfinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
Oncogenic Activation of NF-kappa B
Louis M. Staudt
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Teru Hideshima et al.
BLOOD (2009)
NF-κB p52:RelB heterodimer recognizes two classes of κB sites with two distinct modes
Amanda J. Fusco et al.
EMBO REPORTS (2009)
OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Veronique Baud et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
NF-κB and cancer -: identifying targets and mechanisms
Willscott E. Naugler et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
NF-κB in the pathogenesis and treatment of multiple myeloma
Zhi-Wei Li et al.
CURRENT OPINION IN HEMATOLOGY (2008)
Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
Stephanie Markovina et al.
MOLECULAR CANCER RESEARCH (2008)
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling
Sivakumar Vallabhapurapu et al.
NATURE IMMUNOLOGY (2008)
IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis
Eugene Varfolomeev et al.
CELL (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells
T. Lwin et al.
LEUKEMIA (2007)
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
D. S. Basseres et al.
ONCOGENE (2006)
The alternative NF-κB pathway from biochemistry to biology:: Pitfalls and promises for future drug development
Emmanuel Dejardin
BIOCHEMICAL PHARMACOLOGY (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Shaping alternative NF-κB-dependent gene expression programs:: new clues to specificity
G Natoli et al.
CELL DEATH AND DIFFERENTIATION (2006)
Expression of Pitx2 in stromal cells is required for normal hematopoiesis
A Kieusseian et al.
BLOOD (2006)
RelA repression of RelB activity induces selective gene activation downstream of TNF receptors
E Jacque et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
NFκB:: Linking inflammation and immunity to cancer development and progression
M Karin et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
AC Bharti et al.
BLOOD (2004)
Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers
G Bonizzi et al.
EMBO JOURNAL (2004)
Critical role of RelB serine 368 for dimerization and p100 stabilization
HJ Maier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
RelB/p50 dimers are differentially regulated by tumor necrosis factor-α and lymphotoxin-β receptor activation -: Critical roles for p100
E Derudder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Modulation of NF-κB activity by exchange of dimers
S Saccani et al.
MOLECULAR CELL (2003)
RelB forms transcriptionally inactive complexes with RelA/p65
R Marienfeld et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells
TH Landowski et al.
ONCOGENE (2003)
RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF
ZB Yilmaz et al.
EMBO JOURNAL (2003)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines
DS Weih et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
